Interview with John Montgomery , CEO, Alphapharm
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
Address: Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point NSW 2000
Tel: (602) 9298 3999
Web: http://www.alphapharm.com.au/
Alphapharm has been researching, developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. Alphapharm has become the largest supplier of medicines to the subsidised PBS and Australia’s leader in generic medicines.
Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US.
Globally, Alphapharm is part of Mylan whose broad offering includes the world’s second largest portfolio of active pharmaceutical ingredients (APIs) and a powerful pipeline with more than 200 applications or dossiers pending regulatory approval. The structure of Alphapharm enables the company to leverage Mylan’s global platform while maintaining a very strong emphasis on meeting local market needs and expectations.
Cardiology, Pain Management, Osteoporosis, Smoking Cessation, Weight Management
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to…
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry association for innovative pharmaceutical companies. . Just about every company engaged in…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
Your distinguished career in health research leadership and management has seen you through a variety of prestigious positions, not to mention the Order of Australia. Most recently you were appointed…
Australia, the “land down under” to many Westerners, is sometimes left at just that — out of sight, and out of mind. But investors who ignore Australia do so…
See our Cookie Privacy Policy Here
